Buprenorphine Hydrochloride Tablet
Product Images NDC 0121-1019

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Buprenorphine Hydrochloride (NDC 0121-1019). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pai Holdings, Llc Dba Pharmaceutical Associates, Inc. And Dba Pai Pharma, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Buprenorphine Hydrochloride 1)

Chemical Structure (Buprenorphine Hydrochloride 1)
Chemical structure of buprenorphine hydrochloride, showing its molecular framework including multiple ring systems and functional groups characteristic of the compound.*
FDA Label Image

Figure (Buprenorphine Hydrochloride 2)

Figure (Buprenorphine Hydrochloride 2)
An instructional illustration showing a hand placing a sublingual tablet under the tongue inside an open mouth. The image demonstrates the proper method of administering a sublingual tablet.*
FDA Label Image

Principal Display Panel (2 mg Sublingual Tablet 30-count Bottle Label)

Principal Display Panel (2 mg Sublingual Tablet 30-count Bottle Label)
Label for Buprenorphine Sublingual Tablets, 2 mg, in a package of 30 tablets. The label shows the NDC 0121-1019-30 and identifies the labeler as PAI Holdings, LLC dba Pharmaceutical Associates, Inc. and dba PAI Pharma. It includes instructions for pharmacists to dispense the Medication Guide and storage directions. The label also contains a barcode and caution symbols.*
FDA Label Image

Principal Display Panel (8 mg Sublingual Tablet 30-count Bottle Label)

Principal Display Panel (8 mg Sublingual Tablet 30-count Bottle Label)
Label for Buprenorphine Sublingual Tablets 8 mg by PAI Holdings, LLC, showing that the package contains 30 tablets. The label includes storage instructions, distributor information as PAI Pharma, a warning to dispense the Medication Guide to each patient, and a barcode with associated NDC 0121-2038-30. The tablets are Rx only and controlled as Schedule III substance.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.